48 results
8-K
EX-99.1
RYTM
Rhythm Pharmaceuticals Inc.
22 Feb 24
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
7:01am
of the license revenue.
R&D Expenses: R&D expenses were $29.9 million in the fourth quarter of 2023 and $135.0 million for the year ended December 31, 2023 … are derived from:
GAAP total operating expenses, inclusive of:
SG&A expenses of $105 million to $110 million; and
R&D expenses of $145 million
8-K
EX-99.1
RYTM
Rhythm Pharmaceuticals Inc.
7 Nov 23
Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update
7:05am
to provide update on R&D programs for investors and analysts at an event planned for Dec. 6 --
-- Management to host conference call today at 8:00 a.m … Phase 3 study reinforce our confidence as we advance this high potential program. We look forward to providing an R&D update, including our RM-718
8-K
EX-99.1
vpdlxa3
1 Aug 23
Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business
7:05am
8-K
EX-99.1
yfaxc95wk78sgi4s29c
2 May 23
Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update
7:05am
8-K
EX-99.1
v9p06e
8 Nov 22
Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update
7:03am
8-K
EX-99.1
wteexfv
2 Aug 22
Rhythm Pharmaceuticals Reports Second Quarter 2022 Financial Results and Business Update
7:02am
8-K
EX-99.1
rocybgoh
3 May 22
Rhythm Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Update
7:05am
8-K
EX-99.1
znwm6862zc5hgvn39
2 Nov 21
Rhythm Pharmaceuticals Reports Third Quarter 2021 Financial Results
7:05am
8-K
EX-99.1
vmaegte 1qwe2ood7pgu
3 Aug 21
Rhythm Pharmaceuticals Reports Second Quarter 2021 Financial Results
7:05am
8-K
EX-99.1
ppt5mda
3 May 21
Rhythm Pharmaceuticals Reports First Quarter 2021 Financial Results
8:54am